Literature DB >> 16565497

Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane).

Dina C Nacionales1, Kindra M Kelly, Pui Y Lee, Haoyang Zhuang, Yi Li, Jason S Weinstein, Eric Sobel, Yoshiki Kuroda, Jun Akaogi, Minoru Satoh, Westley H Reeves.   

Abstract

Lymphoid neogenesis is associated with antibody-mediated autoimmune diseases such as Sjogren's syndrome and rheumatoid arthritis. Although systemic lupus erythematosus is the prototypical B-cell-mediated autoimmune disease, the role of lymphoid neogenesis in its pathogenesis is unknown. Intraperitoneal injection of 2,6,10,14-tetramethyl-pentadecane (TMPD, pristane) or mineral oil causes lipogranuloma formation in mice, but only TMPD-treated mice develop lupus. We report that lipogranulomas are a form of lymphoid neogenesis. Immunoperoxidase staining of lipogranulomas revealed B cells, CD4(+) T cells, and dendritic cells and in some cases organization into T- and B-cell zones. Lipogranulomas also expressed the lymphoid chemokines CCL21, CCL19, CXCL13, CXCL12, and CCL22. Expression of the type I interferon (IFN-I)-inducible genes Mx1, IRF7, IP-10, and ISG-15 was greatly increased in TMPD- versus mineral oil-induced lipogranulomas. Dendritic cells from TMPD lipogranulomas underwent activation/maturation with high CD86 and interleukin-12 expression. Magnetic bead depletion of dendritic cells markedly diminished IFN-inducible gene (Mx1) expression. We conclude that TMPD-induced lupus is associated with the formation of ectopic lymphoid tissue containing activated dendritic cells producing IFN-I and interleukin-12. In view of the increased IFN-I production in systemic lupus erythematosus, these studies suggest that IFN-I from ectopic lymphoid tissue could play a role in the pathogenesis of experimental lupus in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565497      PMCID: PMC1606560          DOI: 10.2353/ajpath.2006.050125

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  61 in total

Review 1.  Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines.

Authors:  P Hjelmström
Journal:  J Leukoc Biol       Date:  2001-03       Impact factor: 4.962

2.  Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells.

Authors:  D Jarrossay; G Napolitani; M Colonna; F Sallusto; A Lanzavecchia
Journal:  Eur J Immunol       Date:  2001-11       Impact factor: 5.532

3.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

4.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions.

Authors:  L Farkas; K Beiske; F Lund-Johansen; P Brandtzaeg; F L Jahnsen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane.

Authors:  H B Richards; M Satoh; J C Jennette; B P Croker; H Yoshida; W H Reeves
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

6.  Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse.

Authors:  S A Luther; H L Tang; P L Hyman; A G Farr; J G Cyster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

7.  IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells.

Authors:  Thomas Luft; Petra Luetjens; Hubertus Hochrein; Tracey Toy; Kelly-Anne Masterman; Mark Rizkalla; Charlie Maliszewski; Ken Shortman; Jonathan Cebon; Eugene Maraskovsky
Journal:  Int Immunol       Date:  2002-04       Impact factor: 4.823

8.  Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease.

Authors:  H Yoneyama; K Matsuno; Y Zhang; M Murai; M Itakura; S Ishikawa; G Hasegawa; M Naito; H Asakura; K Matsushima
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

9.  The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment.

Authors:  E S Baekkevold; T Yamanaka; R T Palframan; H S Carlsen; F P Reinholt; U H von Andrian; P Brandtzaeg; G Haraldsen
Journal:  J Exp Med       Date:  2001-05-07       Impact factor: 14.307

10.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  62 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus.

Authors:  Dina C Nacionales; Jason S Weinstein; Xiao-Jie Yan; Emilia Albesiano; Pui Y Lee; Kindra M Kelly-Scumpia; Robert Lyons; Minoru Satoh; Nicholas Chiorazzi; Westley H Reeves
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

3.  A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.

Authors:  Peng Du; Lei Xu; Weiyi Qiu; Dadi Zeng; Junjie Yue; Shuang Wang; Peitang Huang; Zhiwei Sun
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.

Authors:  Deborah Kienhöfer; Jonas Hahn; Julia Stoof; Janka Zsófia Csepregi; Christiane Reinwald; Vilma Urbonaviciute; Caroline Johnsson; Christian Maueröder; Malgorzata J Podolska; Mona H Biermann; Moritz Leppkes; Thomas Harrer; Malin Hultqvist; Peter Olofsson; Luis E Munoz; Attila Mocsai; Martin Herrmann; Georg Schett; Rikard Holmdahl; Markus H Hoffmann
Journal:  JCI Insight       Date:  2017-05-18

5.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer.

Authors:  Juan M Zapata; David Llobet; Maryla Krajewska; Sophie Lefebvre; Christina L Kress; John C Reed
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

6.  Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Authors:  S A Summers; D Odobasic; M B Khouri; O M Steinmetz; Y Yang; S R Holdsworth; A R Kitching
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 7.  Effects of acute and chronic inflammation on B-cell development and differentiation.

Authors:  Derek Cain; Motonari Kondo; Huaiyong Chen; Garnett Kelsoe
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

8.  IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.

Authors:  Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.

Authors:  Pui Y Lee; Yutaro Kumagai; Yi Li; Osamu Takeuchi; Hideo Yoshida; Jason Weinstein; Erinn S Kellner; Dina Nacionales; Tolga Barker; Kindra Kelly-Scumpia; Nico van Rooijen; Himanshu Kumar; Taro Kawai; Minoru Satoh; Shizuo Akira; Westley H Reeves
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

10.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.